Kintor Pharmaceutical Limited



简体

繁体

搜索

PREV 

NEXT 

About Us

Kintor Pharmaceuticals focuses on developing drugs for androgen-receptor-related diseases with significant unmet medical needs，

including prostate cancer, breast cancer, liver cancer, COVID-19, alopecia, acne, and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

Small-molecule drugs

Kintor Pharmaceuticals product pipeline initially focused on androgen receptor (AR) antagonists. Our expanded pipeline now includes mTOR inhibitors, Hedgehog inhibitors, AR protein degradation agents, and cMyc inhibitors.

Innovative biologics

Kintor Pharmaceuticals' first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers.

Combination therapies

To provide the best treatment for prostate, breast, and liver cancers and other diseases, Kintor Pharmaceuticals is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

R&D Platform

Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a multidisciplinary team of drug developers.

Manufacturing Base

Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing base in Suzhou.

Commercial Operation

In anticipation of the commercial launch of our products, Kintor Pharmaceuticals is building an independent commercialization team. [entity?]

R&D Platform

We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.

Manufacturing Base

A modern pharmaceutical manufacturing base in Suzhou which covers an area of about 20,000 ㎡ has been completed following GMP standards and will be ready for production in 2020.

Commercial Operation

In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.

News Center

2022-09-29

Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide for AR+ mBC in EJC

Suzhou, September 29, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the results from a phase Ib study of pruxelutamide (used to be called proxalutamide, GT0918) for the treatment of patients with androgen receptor positive (AR+) metastatic breast cancer (AR+ mBC) in China have been published in the international journal, European Journal of Cancer (2021 Impact Factor: 10.002, EJC) on September 28, 2022, further demonstrating the efficacy and safety of pruxelutamide in patients with AR+ mBC.

2022-08-29

Kintor Pharma Announces 2022 Interim Results and Recent Business Highlights

Suzhou, August 29, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma” or “the Company”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced its 2022 interim results and released an update on its recent business highlights.

2022-08-09

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

Suzhou, August 9, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92 subjects for its phase I clinical trial of GT20029 in China for the treatment of androgenetic alopecia (AGA) and acne on August 8, 2022.